Endo Says New Data To Be Presented Supporting Safety And Tolerability Of BELBUCA

(RTTNews) - Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP, ENL.TO), announced new data to be presented supporting the safety and tolerability of BELBUCA or buprenorphine buccal film for the long-term management of chronic pain in patients requiring around-the-clock opioids. The findings will be presented during a poster session at the International Conference on Opioids (ICOO 2016) in Boston, which takes place June 5-7.

BELBUCA is the first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. In the Phase 3, open-label study, many patients receiving treatment with BELBUCA twice daily reported a low incidence of typical opioid-like side effects such as nausea and vomiting during treatment titration and for up to 48 weeks of daily therapy.

The study also found that BELBUCA was effective during long-term treatment and provided sustained pain relief throughout the treatment phase (48 weeks) as measured on the numeric rating scale (NRS).